Whilst treatment-related thrombocytopenia is a well-established adverse effect of Panobinostat, in this setting of progressive disease it is likely that plasma cell infiltration in bone marrow further contributes to thrombocytopenia by triggering thrombopoietin (TPO) production [25]. The gene discussed is TPO; the disease is Thrombocytopenia.